Developing ground-breaking solutions in the fight against neonatal chronic lung disease.
Half of premature babies under 26 weeks develop neonatal chronic lung disease. This is a debilitating disease and there are no effective treatments to prevent it. These babies are deficient in the natural anti-inflammatory/anti-infective protein, surfactant protein D (SP-D). This protein is lacking in the current therapies. However, we have developed a novel way to produce the functional part of this natural defence protein. Having extensive pre-clinical efficacy data demonstrating the treatment of replacing this deficient protien, using an 'Aid for Start up' Innovate grant we are currently developing a GMC manufacturing procedure and preparing for clinical trials.
Company Details
- Founded
- -
- Address
- Hertfordshire
- in****@****cor.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- trimunocor.com
- HQ
- HERTFORDSHIRE
- Competitors
- MicroMatrices, Plasticell Limited, VIDEREGEN LIMITED.
Trimunocor Ltd Questions
Trimunocor Ltd's website is trimunocor.com
Trimunocor Ltd's LinkedIn profile is https://uk.linkedin.com/company/trimunocor-limited
Trimunocor Ltd's industry is
Biotechnology Research
Trimunocor Ltd's support email address is info@trimunocor.com
Trimunocor Ltd's categories are Biotechnology Research
Trimunocor Ltd's founding year is 2013
